浙江震元(000705.SZ):2020年度淨利預降50%-65%
格隆匯 1 月 29日丨浙江震元(000705.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨利潤7405萬元–1.06億元,同比下降50%-65%;扣除非經常性損益後的淨利潤6085萬元–6694萬元,同比增長0%-10%。
本報吿期與上年相比,生產經營持續穩健發展,盈利能力穩步提升,但歸屬於上市公司股東的淨利潤同向下降的主要原因為:上年同期取得公司下大路及子公司震元製藥勝利西路相關資產拆遷補償款,屬公司非經常性損益,計入2019年度損益。本期無大額拆遷補償款發生,導致本報吿期歸屬於上市公司股東的淨利潤同向下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.